AI-generated analysis. Always verify with the original filing.
Grifols, S.A. reports that its Board of Directors has decided to initiate a process to evaluate a potential Initial Public Offering in the United States of a portion of the shares of its subsidiary, parent of its U.S. Biopharma business, as part of self-sufficiency programs. The transaction is subject to regulatory and legal requirements, internal approvals, and market conditions, with no assurance of completion.